Background and Aim: The incidence of gastric cancer occurring after successful Helicobacter pylori eradication has been increasing. We aimed to clarify the influence of eradication therapy on the ability to diagnose early gastric cancer after successful H. pylori eradication in patients who underwent annual endoscopic screening. Methods: A total of 220 patients (179 men; mean age 71.0 years) had differentiated-type early gastric cancer that was discovered through annual endoscopic screening. Patients were categorized into 2 groups: the H. pylori-eradicated group (n = 81) and the non-eradicated control group (n = 139). After matching patients by propensity scores, we retrospectively analyzed the clinicopathological characteristics of 162 patients (81 patients in each group). Furthermore, we compared the characteristics of gastric cancer with submucosal invasion between the 2 groups. Results: The prevalence of early gastric cancer with submucosal invasion was significantly higher in the eradicated group than in the control group, both before propensity score matching (16.0 vs. 7.2%, respectively; p = 0.038) and after propensity score matching of 81 pairs (16.0 vs. 4.9%, respectively; p = 0.021). In the comparative analysis of gastric cancer with submucosal invasion, there was no difference between the 2 groups with respect to factors influencing the ability to diagnose its presence endoscopically. Conclusion:H. pylori eradication therapy increased the prevalence of differentiated-type gastric cancer with submucosal invasion despite patients’ completion of annual endoscopic screening after eradication.

Journal Section:
Original Paper
Keywords:
Helicobacter pylori eradication, Gastric cancer, Annual endoscopic screening, Endoscopic submucosal dissection, Propensity score matching
1.
International Agency for Research on Cancer. GLOBOCAN 2012 Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.
2.
Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784–789.
3.
Matsuo T, Ito M, Takata S, Tanaka S, Yoshihara M, Chayama K: Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter 2011; 16: 415–419.
4.
Ono S, Kato M, Suzuki M, Ishigaki S, Takahashi M, Haneda M, Mabe K, Shimizu Y: Frequency of Helicobacter pylori-negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic and serological atrophy. Digestion 2012; 86: 59–65.
5.
Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT: Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009; 137: 1641–1648.
6.
Tsuda M, Asaka M, Kato M, Matsushima R, Fujimori K, Akino K, Kikuchi S, Lin Y, Sakamoto N: Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter 2017; 22:e12415.
7.
Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P: Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 2014; 348:g3174.
8.
Shiotani A, Haruma K, Graham DY: Metachronous gastric cancer after successful Helicobacter pylori eradication. World J Gastroenterol 2014; 20: 11552–11559.
9.
Kitamura Y, Ito M, Matsuo T, Boda T, Oka S, Yoshihara M, Tanaka S, Chayama K: Characteristic epithelium with low-grade atypia appears on the surface of gastric cancer after successful Helicobacter pylori eradication therapy. Helicobacter 2014; 19: 289–295.
10.
Kato M, Nishida T, Yamamoto K, Hayashi S, Kitamura S, Yabuta T, Yoshio T, Nakamura T, Komori M, Kawai N, Nishihara A, Nakanishi F, Nakahara M, Ogiyama H, Kinoshita K, Yamada T, Iijima H, Tsujii M, Takehara T: Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer: a multicentre retrospective cohort study by Osaka University ESD study group. Gut 2013; 62: 1425–1432.
11.
Maehata Y, Nakamura S, Fujisawa K, Esaki M, Moriyama T, Asano K, Fuyuno Y, Yamaguchi K, Egashira I, Kim H, Kanda M, Hirahashi M, Matsumoto T: Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc 2012; 75: 39–46.
12.
Maehata Y, Nakamura S, Esaki M, Ikeda F, Moriyama T, Hida R, Washio E, Umeno J, Hirahashi M, Kitazono T, Matsumoto T: Characteristics of primary and metachronous gastric cancers discovered after Helicobacter pylori eradication: a multicenter propensity score-matched study. Gut Liver 2015; 11: 628–634.
13.
Austin PC: Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol 2010; 172: 1092–1097.
14.
Ono H, Yao K, Fujishiro M, Oda I, Nimura S, Yahagi N, Iishi H, Oka M, Ajioka Y, Ichinose M, Matsui T: Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer. Dig Endosc 2016; 28: 3–15.
15.
Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011; 14: 101–112.
16.
Kotachi T, Ito M, Yoshihara M, Boda T, Kiso M, Masuda K, Matsuo T, Tanaka S, Chayama K: Serological evaluation of gastric cancer risk based on pepsinogen and Helicobacter pylori antibody: relationship to endoscopic findings. Digestion 2017; 95: 314–318.
17.
Matsuo T, Ito M, Tatsugami M, Boda T, Takata S, Tanaka S, Chayama K: Gastric cancer development after Helicobacter pylori eradication therapy: a new form of gastric neoplasia. Digestion 2012; 85: 61–67.
18.
Saka A, Yagi K, Nimura S: Endoscopic and histological features of gastric cancers after successful Helicobacter pylori eradication therapy. Gastric Cancer 2016; 19: 524–530.
19.
Hori K, Watari J, Yamasaki T, Kondo T, Toyoshima F, Sakurai J, Ikehara H, Tomita T, Oshima T, Fukui H, Nakamura S, Miwa H: Morphological characteristics of early gastric neoplasms detected after Helicobacter pylori eradication. Dig Dis Sci 2016; 61: 1641–1651.
20.
Ito M, Tanaka S, Takata S, Oka S, Imagawa S, Ueda H, Egi Y, Kitadai Y, Yasui W, Yoshihara M, Haruma K, Chayama K: Morphological changes in human gastric tumours after eradication therapy of Helicobacter pylori in a short-term follow-up. Aliment Pharmacol Ther 2005; 21: 559–566.
21.
Kobayashi M, Hashimoto S, Nishikura K, Mizuno K, Takeuchi M, Sato Y, Ajioka Y, Aoyagi Y: Magnifying narrow-band imaging of surface maturation in early differentiated-type gastric cancers after Helicobacter pylori eradication. J Gastroenterol 2013; 48: 1332–1342.
22.
Sasaki A, Kitadai Y, Ito M, Sumii M, Tanaka S, Yoshihara M, Haruma K, Chayama K: Helicobacter pylori infection influences tumor growth of human gastric carcinomas. Scand J Gastroenterol 2003; 38: 153–158.
23.
Majima A, Handa O, Naito Y, Dohi O, Okayama T, Yoshida N, Kamada K, Katada K, Uchiyama K, Ishikawa T, Takagi T, Konishi H, Yagi N, Itoh Y: Early-stage gastric cancer can be found in improved atrophic mucosa over time from successful Helicobacter pylori eradication. Digestion 2017; 95: 194–200.
24.
Kawai T, Moriyasu F, Tsuchida A: Key Issues associated with Helicobacter pylori eradication. Digestion 2016; 93: 19–23.
25.
Ito M, Takata S, Tatsugami M, Wada Y, Imagawa S, Matsumoto Y, Takamura A, Kitamura S, Matsuo T, Tanaka S, Haruma K, Chayama K: Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy: a systematic review. J Gastroenterol 2009; 44: 365–371.
26.
Kotachi T, Ito M, Boda T, Kiso M, Masuda K, Hata K, Kawamura T, Sanomura Y, Yoshihara M, Tanaka S, Chayama K: Clinical significance of reddish depressed lesions observed in the gastric mucosa after Helicobacter pylori eradication. Digestion 2018; 98: 48–55.
27.
Miura K, Okada H, Kouno Y, Kanzaki H, Iwamuro M, Hori K, Kita M, Kawano S, Kawahara Y, Tanaka T, Yanai H: Actual status of involvement of Helicobacter pylori infection that developed gastric cancer from group A of ABC (D) stratification – Study of early gastric cancer cases that underwent endoscopic submucosal dissection. Digestion 2016; 94: 17–23.
© 2018 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.